Hello and welcome to this special episode of Let’s Talk Rare: The Life Science Podcast as we celebrate 5 years of bringing you the podcast that is now the number one life science podcast across all platforms. We at Partners 4 Access want to thank every single one of our 35,000 subscribers and all the guests who have graced the podcast from the bottom of our hearts, we would not have gotten here without you.
A special episode calls for special guests, and joining us today are our in-house expert and Managing Partner at P4A, Sophie Schmitz, our host from 2018-2021, Aparna Krishnan, and Prasan Subedi, Access Strategy Team Lead at Pfizer. Together, we walk down memory lane and relive the high points and challenges of the past five years, and share insights on rare diseases and cell and gene therapies.
Aparna Krishnan Bio:
Aparna has over 10 years of experience in the pharmaceutical and healthcare industry. As part of the senior leadership team, her primary focus is on strategic corporate engagement, legal, financial operations, and human resources. She has previously worked as Manager of Life Sciences at IHS Markit and as Consultant at Parexel’s Commercialization unit, among others specializing in market access, pricing, and reimbursement.
Sophie Schmitz Bio:
Sophie is the managing partner at Partners 4 Access, a company that believes in a sustainable rare disease world, which means helping our clients unlock the true opportunity of orphan drugs and ATMPs. Her 20+ year career spans various disease areas and medical devices, successfully supporting the strategy development and operationalization for orphan drugs. She brings a wealth of commercial and access experience across orphan and cell and gene therapies to the benefit of clients. She plays an active role in advising clients on price and market access strategies, with the ultimate goal of optimizing fair access for all stakeholders in rare diseases.
The Role of Patient Experience Data in Drug Development with Pina Haberl and Sam Morrison
World EPA Conference 2024 Special
Rare Disease Day Special 2024: The Role of Genetic Diagnosis in Rare Conditions with Nick Meade
Revolutionizing Patient Outcomes: The Power of Digital Health Solutions with RJ Kedziora
The Future of Patient Engagement and the Role of Technology in Healthcare with Iola Forster
Navigating the New EU HTA Regulation and Its Impact on ATMP Development
Alejandro Dorenbaum, CMO of Reneo Pharmaceuticals Discusses Clinical-Stage Therapies
Interview with Xortx Therapeutics CEO, Dr Allen Davidoff discussing their journey from early development to potential launch
World EPA Congress 2023 Special
Rare Disease Day Special 2023
Trends to look out for in 2023
World Orphan Drug Congress Europe 2022 Special
Winds of change for German Healthcare Market!
Part 2 -Patient Empowerment: Is it a no-brainer?
Part 1 Patient Empowerment; Why involving patients from early drug development through to launch is a no-brainer!
What makes P4A an award winning consultancy?
Special Episode with EUCOPE-Part 2 with Alexander Natz
Special series with Eucope: Part 1 featuring Victor Maertens
China market access: obstacle or opportunity for orphan drug, cell and gene therapy manufacturers?
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Museum of the Missing
Strange by Nature Podcast
Sasquatch Chronicles
Hidden Brain